PE20091033A1 - Derivados de nicotinamida como agentes anticancerosos y su preparacion - Google Patents

Derivados de nicotinamida como agentes anticancerosos y su preparacion

Info

Publication number
PE20091033A1
PE20091033A1 PE2008001687A PE2008001687A PE20091033A1 PE 20091033 A1 PE20091033 A1 PE 20091033A1 PE 2008001687 A PE2008001687 A PE 2008001687A PE 2008001687 A PE2008001687 A PE 2008001687A PE 20091033 A1 PE20091033 A1 PE 20091033A1
Authority
PE
Peru
Prior art keywords
nicotinamide
pyridin
phenyl
alkyl
preparation
Prior art date
Application number
PE2008001687A
Other languages
English (en)
Inventor
Jerome Arigon
Claude Bernhart
Monsif Bouaboula
Pierre Casellas
Romain Combet
Sandrine Hilairet
Samir Jegham
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20091033A1 publication Critical patent/PE20091033A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE NICOTINAMIDA DE FORMULA (I), DONDE A ES -NR1R1' O ALCOXI C1-C6; Z Y Z' SON N Y CH, N Y CF, N Y N; CH Y CH, CH Y N; L ES -CH=CH-, -CH2CH2-, -(CH2)n-Y; Y ES O O NH; n ES UN ENTERO DE 1 A 4; R1 Y R1' SON H, ALQUILO C1-C6, CICLOALQUILO C3-C6; ENTRE OTROS; R2 ES -Q-R4; Q ES O O -NH-; R4 ES H, CICLOALQUILO C3-C6, ALQUILO C1-C6, ENTRE OTROS; R3 ES H, F, ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-ETILAMINO-N-METIL-6-[4-(3-PIRIDIN-3-ILMETIL-UREIDO)-FENIL]-NICOTINAMIDA, 2-AMINO-N-METIL-6-[4-(3-PIRIDIN-3-ILMETIL-UREIDO)-FENIL]-NICOTINAMIDA, (2-PIPERIDIN-1-IL-ETIL)AMIDA DEL ACIDO 2-{4-[3-(6-AMINO-PIRIDIN-3-ILMETIL)-UREIDO]-FENIL}-4-ETILAMINO-PIRIMIDIN-5-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2008001687A 2007-09-28 2008-09-26 Derivados de nicotinamida como agentes anticancerosos y su preparacion PE20091033A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706799A FR2921657A1 (fr) 2007-09-28 2007-09-28 Derives de nicotinamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20091033A1 true PE20091033A1 (es) 2009-08-17

Family

ID=39356668

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001687A PE20091033A1 (es) 2007-09-28 2008-09-26 Derivados de nicotinamida como agentes anticancerosos y su preparacion

Country Status (19)

Country Link
US (1) US20100222319A1 (es)
EP (1) EP2205566A2 (es)
JP (1) JP2010540504A (es)
KR (1) KR20100065165A (es)
CN (1) CN101808996A (es)
AR (1) AR066171A1 (es)
AU (1) AU2008334457A1 (es)
BR (1) BRPI0817973A2 (es)
CA (1) CA2700559A1 (es)
CL (1) CL2008002893A1 (es)
FR (1) FR2921657A1 (es)
IL (1) IL204663A0 (es)
MX (1) MX2010003445A (es)
PA (1) PA8797301A1 (es)
PE (1) PE20091033A1 (es)
RU (1) RU2010116765A (es)
TW (1) TW200918056A (es)
UY (1) UY31367A1 (es)
WO (1) WO2009074749A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1945632E (pt) 2005-11-08 2013-12-24 Vertex Pharma Moduladores heterocíclicos de transportadores de cassete de ligação a atp
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
ES2604555T3 (es) * 2007-12-07 2017-03-07 Vertex Pharmaceuticals Incorporated Procedimiento para producir ácidos cicloalquilcarboxiamido-piridinabenzoicos
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
FR2943675A1 (fr) * 2009-03-24 2010-10-01 Sanofi Aventis Composes anticancereux, leur preparation et leur application en therapeutique
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2943670B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives anticancereux,leur preparation et leur application en therapeutique
JP2012529535A (ja) * 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
MX2012010011A (es) * 2010-03-01 2012-10-05 Myrexis Inc Compuestos y usos terapeuticos de los mismos.
ES2604480T5 (es) 2010-04-07 2020-03-17 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
US8827372B2 (en) 2010-07-07 2014-09-09 Frontis Corp. Blowing system
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
SI2573073T1 (sl) * 2011-09-26 2015-02-27 Sanofi Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN103804270B (zh) * 2014-01-23 2016-06-22 中国药科大学 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
JP7092356B2 (ja) 2016-06-22 2022-06-28 フーダン ユニヴァーシティ ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
JP2021523168A (ja) * 2018-05-04 2021-09-02 リメディー プラン, インコーポレーテッドRemedy Plan, Inc. がん幹細胞を標的化するがん治療
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法
MX2022005445A (es) * 2019-11-06 2022-08-10 Remedy Plan Inc Tratamientos contra el cáncer dirigidos a las células madre cancerosas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4301110A1 (de) * 1993-01-18 1994-07-21 Bayer Ag Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin
ES2249059T3 (es) * 1998-12-16 2006-03-16 Bayer Healthcare Ag Nuevos compuestos de bifenilo y analogos de bifenilo como antagonista de integrina.
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
PE20051046A1 (es) * 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Also Published As

Publication number Publication date
UY31367A1 (es) 2009-04-30
AU2008334457A1 (en) 2009-06-18
CA2700559A1 (fr) 2009-06-18
EP2205566A2 (fr) 2010-07-14
PA8797301A1 (es) 2009-05-15
WO2009074749A2 (fr) 2009-06-18
CN101808996A (zh) 2010-08-18
US20100222319A1 (en) 2010-09-02
BRPI0817973A2 (pt) 2019-04-09
FR2921657A1 (fr) 2009-04-03
JP2010540504A (ja) 2010-12-24
CL2008002893A1 (es) 2009-10-16
RU2010116765A (ru) 2011-11-27
KR20100065165A (ko) 2010-06-15
AR066171A1 (es) 2009-07-29
WO2009074749A3 (fr) 2009-08-20
IL204663A0 (en) 2010-11-30
TW200918056A (en) 2009-05-01
MX2010003445A (es) 2010-04-27

Similar Documents

Publication Publication Date Title
PE20091033A1 (es) Derivados de nicotinamida como agentes anticancerosos y su preparacion
CY1117481T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης
PE20091590A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
PE20100562A1 (es) Derivados policiclicos de indazol como inhibidores de erk
RS50672B (sr) Postupak za pripremanje n-fenilpirazol-1-karboksamida
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
EA200901379A1 (ru) Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
PE20091258A1 (es) Derivados de piridina como activadores de la guanilato ciclasa soluble
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20091491A1 (es) Compuestos novedosos que son inhibidores de erk
PE20131463A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
PE20061316A1 (es) Derivados de pirazol como antagonistas del receptor de progesterona
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
NO20082975L (no) Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer

Legal Events

Date Code Title Description
FD Application declared void or lapsed